<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>69(4)</volume><submitter>Kim B</submitter><funding>New Zealand Breast Cancer Foundation</funding><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Deep inspiratory breath-hold (DIBH) has become standard in radiotherapy for left-sided breast cancer to reduce the heart dose. This study evaluated breath-hold stability and reproducibility using Elekta's Active Breathing Coordinator™ (ABC) and its effectiveness and feasibility in left-sided breast cancer patients undergoing radiotherapy.&lt;h4>Methods&lt;/h4>Eligible patients were planned with free breathing (FB) and DIBH protocols. DIBH treatment was considered if the mean heart dose (MHD) was ≥2 Gy on the FB plan. Those who proceeded with DIBH treatment were enrolled for the pilot study. Electronic portal images of DIBH treatment beams were taken using the movie-exposure mode for breath-hold stability and reproducibility analysis. DIBH effectiveness in heart dose reduction and impact on simulation and treatment durations were compared with FB protocol.&lt;h4>Results&lt;/h4>Out of 56 eligible patients, 15 proceeded with DIBH treatment. The mean difference of patient setup within a single breath-hold was 0.4 mm; between different breath-holds of the same beam 1.1 mm and between different days 2.6 mm. DIBH reduced the MHD by 47% and the mean left anterior descending artery (LAD) dose by 35%. DIBH took longer time than FB in simulation and treatment. At least 14% of the eligible patients did not tolerate DIBH during simulation.&lt;h4>Conclusions&lt;/h4>ABC leads to stable and reproducible breath-holds and results in significant heart dose reductions. It may not be tolerated by all patients and has resource implications.</pubmed_abstract><journal>Journal of medical radiation sciences</journal><pagination>502-509</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9714515</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Deep inspiratory breath-hold radiotherapy for left-sided breast cancer: Initial experience with Active Breathing Coordinator™ in a regional hospital.</pubmed_title><pmcid>PMC9714515</pmcid><pubmed_authors>Kim B</pubmed_authors><pubmed_authors>James M</pubmed_authors><pubmed_authors>Little D</pubmed_authors><pubmed_authors>Yi M</pubmed_authors><pubmed_authors>Groen J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Deep inspiratory breath-hold radiotherapy for left-sided breast cancer: Initial experience with Active Breathing Coordinator™ in a regional hospital.</name><description>&lt;h4>Introduction&lt;/h4>Deep inspiratory breath-hold (DIBH) has become standard in radiotherapy for left-sided breast cancer to reduce the heart dose. This study evaluated breath-hold stability and reproducibility using Elekta's Active Breathing Coordinator™ (ABC) and its effectiveness and feasibility in left-sided breast cancer patients undergoing radiotherapy.&lt;h4>Methods&lt;/h4>Eligible patients were planned with free breathing (FB) and DIBH protocols. DIBH treatment was considered if the mean heart dose (MHD) was ≥2 Gy on the FB plan. Those who proceeded with DIBH treatment were enrolled for the pilot study. Electronic portal images of DIBH treatment beams were taken using the movie-exposure mode for breath-hold stability and reproducibility analysis. DIBH effectiveness in heart dose reduction and impact on simulation and treatment durations were compared with FB protocol.&lt;h4>Results&lt;/h4>Out of 56 eligible patients, 15 proceeded with DIBH treatment. The mean difference of patient setup within a single breath-hold was 0.4 mm; between different breath-holds of the same beam 1.1 mm and between different days 2.6 mm. DIBH reduced the MHD by 47% and the mean left anterior descending artery (LAD) dose by 35%. DIBH took longer time than FB in simulation and treatment. At least 14% of the eligible patients did not tolerate DIBH during simulation.&lt;h4>Conclusions&lt;/h4>ABC leads to stable and reproducible breath-holds and results in significant heart dose reductions. It may not be tolerated by all patients and has resource implications.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2025-04-25T17:07:00.929Z</modification><creation>2025-04-06T05:01:50.572Z</creation></dates><accession>S-EPMC9714515</accession><cross_references><pubmed>35607777</pubmed><doi>10.1002/jmrs.597</doi></cross_references></HashMap>